A San Francisco biotech startup called Radical Numerics has administered an AI-designed virus to a human patient suffering from a severe, drug-resistant bacterial infection. Operating under an FDA-authorized compassionate-use pathway led by a physician, this marks what appears to be the first instance of an artificial intelligence-generated organism being deployed directly into a human body as medicine.
The experimental treatment utilized bacteriophages—viruses that exclusively target and destroy specific bacterial strains while leaving human cells and the broader microbiome untouched. Traditional phage therapy requires scouring environmental samples and existing libraries to find a matching virus, a notoriously slow process for patients facing urgent infections. Radical Numerics bypassed this lengthy search by employing its Omnii-1 genome model to rewrite the tail fiber protein of a well-characterized T7 phage, allowing it to specifically target the patient's isolated bacterial strain in a laboratory setting.
Despite the milestone, concrete details regarding the patient's recovery remain scarce. Radical Numerics has declined to disclose the clinical outcome, hospital, or specific physicians involved, citing patient privacy concerns, and the technical report has not yet undergone independent peer review. While outside microbiologists remain cautious until formal data is published, the project highlights a growing push to leverage machine learning models in combating rising antimicrobial resistance.
Comments